Targeted Strategies for Today's Evolving Markets

MissionIR Blog

Monthly Archives: November 2012

Antares Pharma Inc. (ATRS) Video Chart for Friday, May 18, 2012

Posted on November 14, 2012 by MissionIR

ATRS has fallen from July highs, but is holding a solid support around $3.60. Key indicators of trend and momentum are trying to turn bullish on the support, which could lead to an upward move to test resistance around $4.60. … Continue reading →

Posted in Technical Analysis | Leave a comment

Cardium Therapeutics, Inc. (CXM) Presents Q3 Results, Plus Update on Business Activity

Posted on November 14, 2012 by MissionIR

Cardium Therapeutics, a health sciences and regenerative medicine company, today presented financial results for the third quarter, ended September 30, 2012. The company also reported on recent developments, including the acquisition of To Go Brands nutraceutical brand platform, and various … Continue reading →

Posted in Cardium Therapeutics Inc. CXM | Leave a comment

Nanosphere, Inc. (NSPH) Receives FDA Clearance to Market the Verigene CYP2C19 Test

Posted on November 14, 2012 by MissionIR

Nanosphere, a leading provider of advanced molecular diagnostics systems, announced that the U.S. Food and Drug Administration has granted 510(k) clearance, permitting the marketing of the company’s CYP2C19 Nucleic Acid Test on the automated sample-to-result Verigene System. The Verigene CYP2C19 … Continue reading →

Posted in Small Cap News | Leave a comment

China Mobile Games and Entertainment Group, Ltd. (CMGE) Enters Agreement with Disney

Posted on November 14, 2012 by MissionIR

China Mobile Games and Entertainment Group announced that the company has entered into an agreement with The Walt Disney Company. Under the terms of the agreement, CMGE gains the Chinese rights for two popular Disney mobile games. CMGE is focused … Continue reading →

Posted in Small Cap News | Leave a comment

GreeneStone Healthcare Corp. (GRST) Has Specific Road to Growth

Posted on November 13, 2012 by MissionIR

It’s not unusual for companies to talk about growth, pointing to new technologies and market potential. But potential is a nebulous term, often backed up only by a reference to the total number of estimated customers in a given market … Continue reading →

Posted in GreeneStone Healthcare Corp. GRST | Leave a comment

Bellatrix Exploration Ltd. (BXE) Expands Core Position in Willesden Green Cardium and Mannville

Posted on November 13, 2012 by MissionIR

Bellatrix Exploration, the mid-sized, shrewd growth-focused oil and gas E&P with its primary positions in Alberta and Saskatchewan (as well as some assets in the Peace River Arch region of British Columbia), reported entry today into an agreement valued at … Continue reading →

Posted in Small Cap News | Leave a comment

MannKind Corp. (MNKD) and Colby Pharmaceutical Sign Agreement to Develop and Commercialize Cancer Immunotherapy Products

Posted on November 13, 2012 by MissionIR

MannKind is a company that focuses on the discovery, development, and commercialization of therapeutic products for patients with diseases such as diabetes and cancer. The company’s lead product candidate, AFREZZA, is in late stage clinical trials for treatment of adults … Continue reading →

Posted in Small Cap News | Leave a comment

Remarkable Progress Continues for Bellzone Mining PLC (AIM: BZM)

Posted on November 13, 2012 by MissionIR

Bellzone Mining is an exploration and resource development company listed on the London Stock Exchange. A Jersey registered company, Bellzone is engaged in the development of two iron ore and nickel/copper assets in the Republic of Guinea, West Africa. The … Continue reading →

Posted in Small Cap News | Leave a comment

Cardium Therapeutics, Inc. (CXM) to Present Excellagen Posters at Desert Foot 9th Annual High Risk Diabetic Foot Conference

Posted on November 13, 2012 by MissionIR

Cardium Therapeutics, an asset-based health sciences and regenerative medicine company, announced this morning that the company will be displaying two Excellagen® poster presentations at the Desert Foot 2012 High Risk Diabetic Foot Conference being held this week in Phoenix, AZ. … Continue reading →

Posted in Cardium Therapeutics Inc. CXM | Leave a comment

VistaGen Therapeutics, Inc. (VSTA) Announces Enhancement of Predictive Liver Toxicology and Drug Metabolism Bioassay System

Posted on November 13, 2012 by MissionIR

VistaGen Therapeutics, a biotechnology company applying stem cell technology for drug rescue, predictive toxicology, and drug metabolism screening, today announced a significant advance in its development of LiverSafe 3D™, a human liver cell-based bioassay system designed to predict liver toxicity … Continue reading →

Posted in VistaGen Therapeutics Inc. VSTA | Leave a comment